EP3634381A1 - Système à microaiguilles pour appliquer des analogues peptidiques similaires au glucagon - Google Patents

Système à microaiguilles pour appliquer des analogues peptidiques similaires au glucagon

Info

Publication number
EP3634381A1
EP3634381A1 EP18734753.9A EP18734753A EP3634381A1 EP 3634381 A1 EP3634381 A1 EP 3634381A1 EP 18734753 A EP18734753 A EP 18734753A EP 3634381 A1 EP3634381 A1 EP 3634381A1
Authority
EP
European Patent Office
Prior art keywords
controlled release
glucagon
microneedle array
intradermal
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18734753.9A
Other languages
German (de)
English (en)
Inventor
Andreas Henning
Heiko Spilgies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP3634381A1 publication Critical patent/EP3634381A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles

Definitions

  • the present invention relates to a micro needle system (MNS for short) for intradermal administration in a controlled release of glucagon-like peptide analogues.
  • MNS micro needle system
  • the glucagon-like peptide GLP-1 (glucagon like peptide-1) belongs to the intestinal hormones and is formed with GLP-2 in intestinal cells. GLP-1 is an insulinotropic peptide and regulates blood sugar levels. Its physiological task is to maintain a normal glucose homeostasis and a balanced energy balance. GLP-1 inhibits glucagon secretion and delays gastric emptying. GLP-1 is not suitable as a therapeutic because it has an extremely short half-life of about one minute.
  • GLP-1 glycine-1
  • DPP IV degradative peptidase DPP IV
  • marginal molecular changes such as the replacement of an amino acid make the molecule resistant to peptidase.
  • Some of the previously developed GLP-1 analogs are more potent than the body's own GLP-1 and are used as antidiabetics, but must be administered subcutaneously.
  • Such antidiabetics based on glucagon-like peptide analogs or antagonists - also called incretin mimetics - are in particular exenatide, liraglutide and lixisenatide (hereafter: glucagon-like-peptide analogues) and bind to the GLP-1 receptor.
  • glucagon-like peptide analogs have up to 50 amino acids and a molecular weight of up to 5 kDa. The half-life is usually more than 12 hours.
  • Exanetide is preferred according to the invention.
  • the skin consists of several layers. The utmost
  • the stratum corneum which is a complex structure of compacted keratotic cell debris approximately 10-30 microns thick, forms a watertight membrane to protect the body.
  • Microneedle systems which consist of a microneedle array (MNA) and possibly other components, can by means of a pressure force the microneedles (also:
  • MNA microneedle arrays
  • MNS Microneedle systems
  • MNS can be used for controlled release. Especially for glucagon-like Peptide analogs have a high need for controlled release, especially for more than 12 hours (short: h) or even 24 hours, so that an antidiabetic effect for one day can be achieved or supported.
  • Polyvinylpyrrolidone (short: PVP) is not possible.
  • PVP is preferable for influencing the release of active ingredients compared to PVA and has a higher suitability for this purpose.
  • MNS microneedle system
  • glucagon-like peptide analogues together with the PVP is the subject of the formulation of the MNA and consequently is inherent to the MNA or forms a unit with the MNA.
  • the MNA can be designed to be monotonous or one-piece.
  • the invention therefore relates to a microneedle system containing an MNA for use in the intradermal
  • a controlled release application comprising or consisting of a formulation of PVP and at least one glucagon-like peptide analog.
  • the invention comprises a means comprising
  • Microneedle array comprising or consisting of a
  • Formulation of PVP and at least one glucagon-like Peptide analogs for use in controlled release intradermal administration are provided.
  • Such an agent is, for example, a drug or antidiabetic comprising a protruding microneedle array for the controlled release of at least one glucagon-like peptide analog in an intradermal application.
  • the said medicament is used for the prophylaxis and treatment of diabetes, type II diabetes, insulin resistance,
  • intracutaneous administration describes according to the invention the administration of substances, here: glucagon-like peptide analogues from the MNA into the skin and requires puncturing of the microneedles into the skin.
  • Invention means that the active ingredient, here: glucagon-like peptide analogues, over a period of more than 2 h, preferably more than 12 h, in particular 24 h
  • the invention relates to an agent for use in the controlled release intradermal administration, wherein the controlled release period is more than 2 hours, preferably more than 12 hours, in particular 24 hours.
  • a dose of up to 50 pg / MNA can be administered to glucagon-like peptide analogs in humans.
  • the invention also provides a method for the controlled release of at least one glucagon-like peptide analogs in an intradermal application comprising a microneedle array comprising or consisting of a formulation of PVP and at least one glucagon-like peptide analogues.
  • the invention also relates to a method for
  • the formulation may consist of any PVP having a molecular weight greater than 10,000 Da.
  • the proportion of PVP (weight%) in the formulation may be 50-99%, in particular 70-90%, preferably 75-80%.
  • the PVP content is dependent on the residual water. Typical residual water content may be 5-20%, in particular 12-18%. At a residual water content of 16%, the PVP content is about 76% or lower, if necessary.
  • the formulation may contain auxiliaries and additives, such as
  • Binders or emulsifiers e.g. Carboxymethylcellulose, alginates, gelatin,
  • Humectants eg glycerol, urea, trehalose, c. ) Wetting agents, eg cetyl alcohol, glycerol monostearate, d. ) Antioxidants, such as ascorbic acid, vitamin E. However, preferred are poloxamers, alginates and polysorbates (Tween).
  • the proportion of poloxamer in the formulation may be 2-7%.
  • the proportion of alginate in the formulation may be 2-7%.
  • the proportion of polysorbates in the formulation can be 0.1-1%.
  • applicator systems for applying the microneedle array (MNA) according to the invention under pressure to the skin can be used and result in a sudden load on the skin.
  • the microneedle system comprising a microneedle array is configured with an applicator.
  • Such applicators advantageously allow activation of a pressure mechanism to penetrate the microneedle array into the skin or stratum corneum (see, for example, WO2008091602A2, WO2016162449A1).
  • the applicator system comprising a microneedle array can be configured with conventional functional objects which allow fixation on the skin as well as easy handling for pressure exertion on the skin and in particular can contain at least one fixative.
  • an applicator system is one such system that includes a device that causes the microneedle array to be delivered to the skin for administration of glucagon-like peptide analogs and applied intradermally.
  • the applicator system may comprise a triggering device which is controlled electrically or mechanically.
  • the applicator system may include a plunger which applies or applies the microneedle array to the skin so that the microneedles penetrate into the skin.
  • the triggering device may comprise, for example, a pump, a syringe or a spring, so that a piston stroke can take place with sufficient energy.
  • the plunger may be of any shape and nature and is primarily intended to provide the microneedle array from a first position to a second position for delivery of the active ingredients to the skin.
  • the applicator system may further include a push button or thread.
  • the microneedle array may contain fixing means, which are preferably fixed by means of a pressure-sensitive adhesive strip or plaster on the skin of a patient or volunteers, also called needle plasters.
  • pressure-sensitive adhesives are highly viscous substances that stick to the skin after a short light pressure, so-called pressure-sensitive adhesives (PSA). They have high cohesive and adhesive forces.
  • PSA pressure-sensitive adhesives based on poly (meth) acrylates based on polyisobutylenes or based on silicones can be used.
  • the fixing means may consist of a band, elastic band, rubber or belt. Such fixatives can be used to secure attachment to the body.
  • Such applicator systems allow the secure positioning of the MNA of the invention for controlled release of glucagon-like peptide analogs.
  • the following examples and figures are intended to explain the invention in more detail, but without limiting it.
  • FIG. 1 shows in-vitro results for formulation F1, F2 and F3, which demonstrate a slower, timed release of the active substance exenatide over a time interval of up to 24 hours.
  • the formulations are shown in Table 1.
  • 2AGT sodium alginate, glycerol, Tween (80)
  • composition of the microneedles includes the following:
  • Polylvinylpyrrolidone (PVP) Type 1 MW 20-60 kDa; Type 2:
  • Active substance exenatide with 50 pg is as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un système à microaiguilles (abrév. : MNS) utilisé pour l'application intradermique, dans le cadre d'une libération contrôlée, d'analogues peptidiques similaires au glucagon.
EP18734753.9A 2017-06-07 2018-06-06 Système à microaiguilles pour appliquer des analogues peptidiques similaires au glucagon Pending EP3634381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017112573.6A DE102017112573A1 (de) 2017-06-07 2017-06-07 Mikronadelsystem zur Applikation von Glukagon-ähnlichen-Peptid Analoga
PCT/EP2018/064919 WO2018224559A1 (fr) 2017-06-07 2018-06-06 Système à microaiguilles pour appliquer des analogues peptidiques similaires au glucagon

Publications (1)

Publication Number Publication Date
EP3634381A1 true EP3634381A1 (fr) 2020-04-15

Family

ID=62778874

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18734753.9A Pending EP3634381A1 (fr) 2017-06-07 2018-06-06 Système à microaiguilles pour appliquer des analogues peptidiques similaires au glucagon

Country Status (8)

Country Link
US (2) US20200129424A1 (fr)
EP (1) EP3634381A1 (fr)
JP (2) JP2020522354A (fr)
CN (1) CN110769812A (fr)
BR (1) BR112019025606A2 (fr)
CA (1) CA3066515A1 (fr)
DE (1) DE102017112573A1 (fr)
WO (1) WO2018224559A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111053891A (zh) * 2019-11-15 2020-04-24 浙江工业大学 治疗糖尿病的多肽纳米粒、多肽纳米粒微针及其制备方法
DE102021118997A1 (de) 2021-07-22 2023-01-26 Lts Lohmann Therapie-Systeme Ag. Mikronadelarray mit Antiseptika
CN114699510A (zh) * 2021-12-29 2022-07-05 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4829497B2 (ja) 2002-06-25 2011-12-07 セラジェクト， インコーポレイテッド 薬物送達のための急速に溶解する微小穿孔器および他の適用
WO2007024899A2 (fr) * 2005-08-23 2007-03-01 The General Hospital Corporation Utilisation de glp-1, derives de glp-1 ou fragments de glp-1 aux fins de regeneration de la peau ou stimulation de la croissance des poils ou de traitement des diabetes
EP2015803A4 (fr) * 2006-05-09 2009-05-06 Apogee Technology Inc Structures de nanofibres présentes sur des aspérités destinées à séquestrer, porter et transférer des substances
AU2008209537B2 (en) 2007-01-22 2013-01-31 Corium Pharma Solutions, Inc. Applicators for microneedle arrays
US20090136554A1 (en) * 2007-10-23 2009-05-28 Alza Corporation Transdermal sustained release drug delivery
ES2691388T3 (es) 2008-10-07 2018-11-27 Tuo Jin Microagujas poliméricas de transición de fases
EP2679270B1 (fr) * 2011-02-24 2016-11-09 Hisamitsu Pharmaceutical Co., Inc. Composition d'analogue de glp-1 pour des dispositifs de micro aiguille
TW201620508A (zh) * 2014-02-27 2016-06-16 Hisamitsu Pharmaceutical Co 微刺針
CN104069585B (zh) * 2014-07-03 2017-12-12 台州薇凯生物科技有限公司 可分离式微针系统及其制造方法
JP6712224B2 (ja) * 2014-09-11 2020-06-17 久光製薬株式会社 マイクロニードルデバイス
CA2982803C (fr) 2015-04-07 2023-02-28 Lts Lohmann Therapie-Systeme Ag Systeme a microaiguilles pour l'application de formulations liquides
CN106474620A (zh) * 2016-09-22 2017-03-08 北京化工大学 一种药物可控释放的聚合物微针、制备方法及微针贴片

Also Published As

Publication number Publication date
US20200129424A1 (en) 2020-04-30
DE102017112573A1 (de) 2018-12-13
BR112019025606A2 (pt) 2020-06-16
US20240139098A1 (en) 2024-05-02
CN110769812A (zh) 2020-02-07
JP2020522354A (ja) 2020-07-30
WO2018224559A1 (fr) 2018-12-13
CA3066515A1 (fr) 2018-12-13
JP2023134783A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
EP2349324B1 (fr) Combinaison d'une insuline et d'un agoniste de glp-1
EP1178783B1 (fr) Dispositif et utilisation pour augmenter la permeation transdermique de medicaments
EP3417871B1 (fr) Composition pharmaceutique comprenant un agoniste glp-1, de l'insuline et de la methionine
US20240139098A1 (en) Microneedle system for applying glucagon-like peptide analogues
DE102006026578B4 (de) Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
EP0186019A2 (fr) Pansement médicamenteux
WO2011003820A1 (fr) Préparations d'insuline stables à la chaleur et aux agitations
WO2019025625A1 (fr) Système d'application contenant une matrice de micro-aiguilles présentant un principe actif pour la cicatrisation
EP1971328B1 (fr) Système thérapeutique percutané pour des substances volatiles et/ou thermolabiles
EP2506839A2 (fr) Systeme therapeutique transdermique pour l'administration de peptides
EP3781127B1 (fr) Système de microaiguille pour l'application d'interféron
EP3713549A1 (fr) Système thérapeutique transdermique à base de matrices plastifiant-polymère adhésives
EP2533771B1 (fr) Système thérapeutique transdermique pour l'administration de peptides
EP3448358B1 (fr) Forme d'enrichissement sous forme de film destinee a l'administration transmuqueuse d'anti-diabetiques de peptide
DE102022100991A1 (de) Einrichtung zur kontrollierten Verabreichung eines blutzuckersenkenden Wirkstoffes
DE102021128912A1 (de) Okklusives pflaster mit flexibler backing
DE102021128911A1 (de) Diclofenac enthaltendes tts mit dimethylpropylenharnstoff
DE4406332C1 (de) Pharmazeutische Verwendung von Nitroglycerin zur Verhinderung unerwünschter Wehentätigkeit bei Säugern in einer transdermalen Applikationsform
Sauer Applikation von Normal-und Verzögerungsinsulin per injectionem—vorwiegend unter pharmakokinetischen Aspekten
DE202015009065U1 (de) Klebeband enthaltend Beinwell bzw. Beinwellwurzelextrakt
DE102009038210A1 (de) Kombination von einem Insulin und einem GLP-1-Agonisten
AT10260U1 (de) Transdermales pflaster

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230201